Relay Therapeutics, Inc. RLAY EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s EPS (diluted)?
- Relay Therapeutics, Inc. (RLAY) reported EPS (diluted) of -$0.41 in Q1 2026.
- How has Relay Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Relay Therapeutics, Inc.'s EPS (diluted) increased by 10.9% year-over-year, from -$0.46 to -$0.41.
- What is the long-term trend for Relay Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s EPS (diluted) has grown at a -19.6% compound annual growth rate (CAGR), from -$3.85 to -$1.61.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.